Literature DB >> 10427620

Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis.

A Lennertz1, K G Parhofer, W Samtleben, T Bosch.   

Abstract

Chylomicronemia syndrome (CMS) is a rare disorder characterized by the presence of chylomicrons in the fasting state causing a milky appearance of plasma, eruptive xanthomas, and hepatosplenomegaly; an acute and potentially life threatening complication is severe acute pancreatitis. The underlying defects are inborn errors of metabolism such as deficiencies of lipoprotein lipase (LPL) or apoprotein C-II (apo C-II) as well as familial hypertriglyceridemia. Moreover, CMS can be precipitated when mild hypertriglyceridemia is exacerbated by additional factors such diabetes mellitus, ethanol abuse, or pregnancy. The purpose of the present study was to retrospectively analyze the results of therapeutic plasma exchange (TPE) in 5 patients transferred to our hospital for severe acute pancreatitis due to chylomicronemia syndrome. In a total of 7 TPE sessions, on average 3,286 +/- 247 ml of plasma (i.e., about 1 patient plasma volume) were treated per session. Triglyceride (TG) levels were decreased from 4,972 +/- 2,469 mg/dl on admission to 1,614 +/- 1,276 mg/dl (-70%) after the TPE sessions, and a further decrease was achieved by conservative treatment. Part of the TG reducing effect of the treatment was probably due to heparin induced lipolysis. Acute pancreatitis was resolved in all cases, and 1 pregnant patient delivered without problems at term. In summary, 1 or 2 TPE sessions sufficed to substantially decrease the bulk of triglycerides in acutely exacerbated chylomicronemia syndrome causing a rapid resolution of acute severe pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427620     DOI: 10.1046/j.1526-0968.1999.00158.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  21 in total

1.  Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis.

Authors:  Jui-Hao Chen; Jiann-Horng Yeh; Hsin-Wen Lai; Chao-Sheng Liao
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

2.  Lipemic Serum in Hypertriglyceridemia-Induced Pancreatitis.

Authors:  Michael A Santos; Nisarg B Patel; Carolina Correa
Journal:  J Gen Intern Med       Date:  2017-06-02       Impact factor: 5.128

Review 3.  Necrotizing pancreatitis during pregnancy: a rare cause and review of the literature.

Authors:  F E Gosnell; B B O'Neill; H W Harris
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

Review 4.  Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies.

Authors:  Prashanth Rawla; Tagore Sunkara; Krishna Chaitanya Thandra; Vinaya Gaduputi
Journal:  Clin J Gastroenterol       Date:  2018-06-19

5.  Acute Pancreatitis Secondary to Severe Hypertriglyceridaemia in a Patient with Type 1a Glycogen Storage Disease: Emergent Use of Plasmapheresis.

Authors:  E Rivers; B C Reynolds; S Bunn; N J Leech; J Straker; H J Lambert
Journal:  JIMD Rep       Date:  2017-10-14

Review 6.  Chylomicronaemia--current diagnosis and future therapies.

Authors:  Amanda J Brahm; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2015-03-03       Impact factor: 43.330

7.  Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis.

Authors:  Hakan Alagözlü; Mehmet Cindoruk; Tarkan Karakan; Selahattin Unal
Journal:  Dig Dis Sci       Date:  2006-05-03       Impact factor: 3.199

8.  Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin.

Authors:  Sule Unal; Benan Bayrakci; Umit Yasar; Tevfik Karagoz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  [Update dyslipidemia].

Authors:  K G Parhofer
Journal:  Internist (Berl)       Date:  2013-09       Impact factor: 0.743

Review 10.  The Diagnosis and Treatment of Hypertriglyceridemia.

Authors:  Klaus G Parhofer; Ulrich Laufs
Journal:  Dtsch Arztebl Int       Date:  2019-12-06       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.